Solid Biosciences is a clinical-stage biopharmaceutical company developing gene therapies for rare neuromuscular diseases. Its lead programs target Duchenne muscular dystrophy using adeno-associated virus (AAV) vectors to deliver functional gene constructs to muscle tissue. The company serves a highly specialized patient population with limited disease-modifying options and currently reports negligible product revenue while advancing its pipeline.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -39.5 | — |
| Q3 2025 | 0 | — | -45.8 | — |
| Q4 2025 | 0 | — | -49.8 | — |
| Q1 2026 | 0 | — | -56.7 | — |
| Q2 2026 | 0 | — | -54.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Robostrategy, Inc. (BOT), Satellogic Inc. (SATL), Zevra Therapeutics, Inc. (ZVRA), First Business Financial Services, Inc. (FBIZ), Anteris Technologies Global Corp. (AVR), Greene County Bancorp, Inc. (GCBC)